Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative

Tine Cuppens; Daniela Annibali; An Coosemans; Jone Trovik; Natalja ter Haar; Eva Colas; Angel Garcia-Jimenez; Koen Van de Vijver; Roy P. M. Kruitwagen; Mariel Brinkhuis; Michal Zikan; Pavel Dundr; Jutta Huvila; Olli Carpen; Johannes Haybaeck; Farid Moinfar; Helga B. Salvesen; Maciej Stukan; Carole Mestdagh; Ronald P. Zweemer; Leonardus F. Massuger; Michael R. Mallmann; Eva Wardelmann; Miriam Mints; Godelieve Verbist; Debby Thomas; Ellen Gomme; Els Hermans; Philippe Moerman; Tjalling Bosse; Frederic Amant

doi:10.1158/1078-0432.CCR-16-2149

Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative

Tine Cuppens, Daniela Annibali, An Coosemans, Jone Trovik, Natalja ter Haar, Eva Colas, Angel Garcia-Jimenez, Koen Van de Vijver, Roy P. M. Kruitwagen, Mariel Brinkhuis, Michal Zikan, Pavel Dundr, Jutta Huvila, Olli Carpen, Johannes Haybaeck, Farid Moinfar, Helga B. Salvesen, Maciej Stukan, Carole Mestdagh, Ronald P. ZweemerLeonardus F. Massuger, Michael R. Mallmann, Eva Wardelmann, Miriam Mints, Godelieve Verbist, Debby Thomas, Ellen Gomme, Els Hermans, Philippe Moerman, Tjalling Bosse, Frederic Amant^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1274-1285
Number of pages	12
Journal	Clinical Cancer Research
Volume	23
Issue number	5
DOIs	https://doi.org/10.1158/1078-0432.CCR-16-2149
Publication status	Published - 1 Mar 2017

Keywords

ENDOMETRIAL STROMAL SARCOMA
SOFT-TISSUE SARCOMA
GROWTH-FACTOR RECEPTOR
AKT-MTOR PATHWAY
MAMMALIAN TARGET
BREAST-CANCER
CYCLIN D1
EXPRESSION
TUMORS
TRIAL

Access to Document

10.1158/1078-0432.CCR-16-2149

Cite this

Cuppens, T., Annibali, D., Coosemans, A., Trovik, J., ter Haar, N., Colas, E., Garcia-Jimenez, A., Van de Vijver, K., Kruitwagen, R. P. M., Brinkhuis, M., Zikan, M., Dundr, P., Huvila, J., Carpen, O., Haybaeck, J., Moinfar, F., Salvesen, H. B., Stukan, M., Mestdagh, C., ... Amant, F. (2017). Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative. Clinical Cancer Research, 23(5), 1274-1285. https://doi.org/10.1158/1078-0432.CCR-16-2149

Cuppens, Tine ; Annibali, Daniela ; Coosemans, An ; Trovik, Jone ; ter Haar, Natalja ; Colas, Eva ; Garcia-Jimenez, Angel ; Van de Vijver, Koen ; Kruitwagen, Roy P. M. ; Brinkhuis, Mariel ; Zikan, Michal ; Dundr, Pavel ; Huvila, Jutta ; Carpen, Olli ; Haybaeck, Johannes ; Moinfar, Farid ; Salvesen, Helga B. ; Stukan, Maciej ; Mestdagh, Carole ; Zweemer, Ronald P. ; Massuger, Leonardus F. ; Mallmann, Michael R. ; Wardelmann, Eva ; Mints, Miriam ; Verbist, Godelieve ; Thomas, Debby ; Gomme, Ellen ; Hermans, Els ; Moerman, Philippe ; Bosse, Tjalling ; Amant, Frederic. / Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 5. pp. 1274-1285.

@article{53b514b278524988855e78376c484bf3,

title = "Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative",

keywords = "ENDOMETRIAL STROMAL SARCOMA, SOFT-TISSUE SARCOMA, GROWTH-FACTOR RECEPTOR, AKT-MTOR PATHWAY, MAMMALIAN TARGET, BREAST-CANCER, CYCLIN D1, EXPRESSION, TUMORS, TRIAL",

author = "Tine Cuppens and Daniela Annibali and An Coosemans and Jone Trovik and {ter Haar}, Natalja and Eva Colas and Angel Garcia-Jimenez and {Van de Vijver}, Koen and Kruitwagen, {Roy P. M.} and Mariel Brinkhuis and Michal Zikan and Pavel Dundr and Jutta Huvila and Olli Carpen and Johannes Haybaeck and Farid Moinfar and Salvesen, {Helga B.} and Maciej Stukan and Carole Mestdagh and Zweemer, {Ronald P.} and Massuger, {Leonardus F.} and Mallmann, {Michael R.} and Eva Wardelmann and Miriam Mints and Godelieve Verbist and Debby Thomas and Ellen Gomme and Els Hermans and Philippe Moerman and Tjalling Bosse and Frederic Amant",

year = "2017",

month = mar,

day = "1",

doi = "10.1158/1078-0432.CCR-16-2149",

language = "English",

volume = "23",

pages = "1274--1285",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "5",

}

Cuppens, T, Annibali, D, Coosemans, A, Trovik, J, ter Haar, N, Colas, E, Garcia-Jimenez, A, Van de Vijver, K, Kruitwagen, RPM, Brinkhuis, M, Zikan, M, Dundr, P, Huvila, J, Carpen, O, Haybaeck, J, Moinfar, F, Salvesen, HB, Stukan, M, Mestdagh, C, Zweemer, RP, Massuger, LF, Mallmann, MR, Wardelmann, E, Mints, M, Verbist, G, Thomas, D, Gomme, E, Hermans, E, Moerman, P, Bosse, T & Amant, F 2017, 'Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative', Clinical Cancer Research, vol. 23, no. 5, pp. 1274-1285. https://doi.org/10.1158/1078-0432.CCR-16-2149

Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative. / Cuppens, Tine; Annibali, Daniela; Coosemans, An; Trovik, Jone; ter Haar, Natalja; Colas, Eva; Garcia-Jimenez, Angel; Van de Vijver, Koen; Kruitwagen, Roy P. M.; Brinkhuis, Mariel; Zikan, Michal; Dundr, Pavel; Huvila, Jutta; Carpen, Olli; Haybaeck, Johannes; Moinfar, Farid; Salvesen, Helga B.; Stukan, Maciej; Mestdagh, Carole; Zweemer, Ronald P.; Massuger, Leonardus F.; Mallmann, Michael R.; Wardelmann, Eva; Mints, Miriam; Verbist, Godelieve; Thomas, Debby; Gomme, Ellen; Hermans, Els; Moerman, Philippe; Bosse, Tjalling; Amant, Frederic.

In: Clinical Cancer Research, Vol. 23, No. 5, 01.03.2017, p. 1274-1285.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative

AU - Cuppens, Tine

AU - Annibali, Daniela

AU - Coosemans, An

AU - Trovik, Jone

AU - ter Haar, Natalja

AU - Colas, Eva

AU - Garcia-Jimenez, Angel

AU - Van de Vijver, Koen

AU - Kruitwagen, Roy P. M.

AU - Brinkhuis, Mariel

AU - Zikan, Michal

AU - Dundr, Pavel

AU - Huvila, Jutta

AU - Carpen, Olli

AU - Haybaeck, Johannes

AU - Moinfar, Farid

AU - Salvesen, Helga B.

AU - Stukan, Maciej

AU - Mestdagh, Carole

AU - Zweemer, Ronald P.

AU - Massuger, Leonardus F.

AU - Mallmann, Michael R.

AU - Wardelmann, Eva

AU - Mints, Miriam

AU - Verbist, Godelieve

AU - Thomas, Debby

AU - Gomme, Ellen

AU - Hermans, Els

AU - Moerman, Philippe

AU - Bosse, Tjalling

AU - Amant, Frederic

PY - 2017/3/1

Y1 - 2017/3/1

KW - ENDOMETRIAL STROMAL SARCOMA

KW - SOFT-TISSUE SARCOMA

KW - GROWTH-FACTOR RECEPTOR

KW - AKT-MTOR PATHWAY

KW - MAMMALIAN TARGET

KW - BREAST-CANCER

KW - CYCLIN D1

KW - EXPRESSION

KW - TUMORS

KW - TRIAL

U2 - 10.1158/1078-0432.CCR-16-2149

DO - 10.1158/1078-0432.CCR-16-2149

M3 - Article

C2 - 28232476

VL - 23

SP - 1274

EP - 1285

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -